Advacal (AAACa)
Over the years there has been considerable attention
given to the use issue of calcium effectiveness and bioavalability.
In this small (N11), four week pilot study, the novel Japanese
form of calcium (AAACa) was compared with calcium citrate. The
end points of this pilot study were alterations to bone resorption,
intact parathyroid hormone and first morning urine pH.
In each case, the subject received 900 mg of elemental
calcium in a dosing regiment of 150 mg with each meal, and 450
mg at bedtime. This dosing regimen was likely an important factor
in producing a consistent reduction in bone resorption within
only four weeks.
In this small study formal statistical analysis
was not able to detect a significant difference between the
effects of these two forms of calcium on any end point studied.
From a case study perspective, however, there
was a trend favoring AAACa over calcium citrate in reducing
bone resorption markers. Specifically:
